PMID-14709577 – Ziconotide for Refractory Cancer Pain RCT
Staats PS et al. "Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial," JAMA, 2004;291(1):63-70. doi:10.1001/jama.291.1.63
Quick Reference
| Property | Value |
|---|---|
| PMID | 14709577 |
| DOI | 10.1001/jama.291.1.63 |
| Year | 2004 |
| Journal | JAMA |
| Study Type | Randomized Controlled Trial |
| Evidence Level | I |
| Sample | n=111 patients with refractory cancer or AIDS pain |
| Peptide(s) Studied | Ziconotide (Prialt) — synthetic omega-conotoxin MVIIA, a peptide derived from cone snail venom |
Key Findings
- Intrathecal ziconotide significantly improved Visual Analog Scale of Pain Intensity (VASPI) scores: 53.1% improvement vs 18.1% with placebo (p<0.001)
- 52.9% of ziconotide patients achieved moderate-to-complete pain relief (>=30% improvement) vs 17.5% of placebo patients
- The analgesic effect was rapid, with significant pain reduction observed within the first few days of treatment
- Ziconotide is a synthetic 25-amino acid peptide derived from Conus magus (cone snail) venom that selectively blocks N-type voltage-gated calcium channels (Cav2.2) in the dorsal horn of the spinal cord
- Common adverse effects included dizziness (47%), nausea (30%), confusion (33%), and nystagmus (23%) — largely CNS-related due to the intrathecal route
- This trial led to FDA approval of ziconotide (Prialt) in December 2004 for severe chronic pain in patients intolerant of or refractory to other therapies
- Ziconotide represents one of the first FDA-approved peptide analgesics and demonstrates the therapeutic potential of venom-derived peptides
Study Design
Multicenter, double-blind, placebo-controlled RCT. Patients with refractory cancer or AIDS-related pain despite opioid therapy were randomized to intrathecal ziconotide (titrated from 0.1 mcg/hr up to 0.8 mcg/hr) or placebo, administered via implanted or external microinfusion pump. Treatment duration was 11 days, with a subsequent open-label extension. Primary endpoint was improvement in VASPI score.
Limitations
- Short treatment duration (11 days) in the double-blind phase limits assessment of long-term efficacy and safety
- Intrathecal administration requires specialized equipment (pump) and expertise, limiting accessibility
- High rate of CNS adverse events (dizziness, confusion, nystagmus) may limit tolerability
- Mixed cancer and AIDS pain population; effects may differ by pain etiology
- Narrow therapeutic index requiring careful dose titration
Clinical Relevance
This JAMA-published RCT established ziconotide as the first FDA-approved intrathecal analgesic peptide. It demonstrates that peptides derived from natural sources (cone snail venom) can be developed into approved therapeutics for severe, refractory conditions. The 53.1% vs 18.1% improvement in pain intensity is clinically meaningful for patients who have exhausted other options. For the peptide therapy field, ziconotide exemplifies the therapeutic potential of bioactive peptides beyond the typical growth factor and hormone categories. Its mechanism (N-type calcium channel blockade) is non-opioid, making it relevant for the opioid-sparing pain management paradigm.
Related
#research #RCT #evidence-level-I #cancer #ziconotide #pain